203661-67-0

Basic information

• Product Name: TERT-BUTYL 5-HYDROXYHEXAHYDRO-1H-ISOINDOLE-2(3H)-CARBOXYLATE
• Synonyms: TERT-BUTYL 5-HYDROXYHEXAHYDRO-1H-ISOINDOLE-2(3H)-CARBOXYLATE;tert-butyl hexahydro-6-hydroxy-1H-isoindole-2(3H)-carboxylate
• CAS NO: 203661-67-0
• Molecular Formula: C13H23NO3
• Molecular Weight: 241.32662
• Mol File: 203661-67-0.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: TERT-BUTYL 5-HYDROXYHEXAHYDRO-1H-ISOINDOLE-2(3H)-CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: TERT-BUTYL 5-HYDROXYHEXAHYDRO-1H-ISOINDOLE-2(3H)-CARBOXYLATE(203661-67-0)
• EPA Substance Registry System: TERT-BUTYL 5-HYDROXYHEXAHYDRO-1H-ISOINDOLE-2(3H)-CARBOXYLATE(203661-67-0)

Safety Data

• Hazardous Substances Data: 203661-67-0(Hazardous Substances Data)

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 10533-30-9 2,3,3a,4,7,7a-hexahydro-1H-isoindole 
• 85-40-5 1,2,3,6-tertahydrophthalimide 

Downstream Products

• 203661-68-1 tert-butyl 5-oxohexahydro-1H-isoindole-2(3H)-carboxylate 

Relevant articles and documents

FXR RECEPTOR MODULATOR, PREPARATION METHOD THEREFOR, AND USES THEREOF

The present disclosure disclosed a modulator of FXR receptor and preparation and use thereof, which relates to the technical filed of medicinal chemistry. The present disclosure provides a modulator of FXR receptor having a structural formula I or a pharmaceutically acceptable salt, stereoisomer, solvate or prodrug thereof, which can combine with FXR receptor (that is NR1H4) and be acted as a FXR agonist or a partial agonist for preventing and treating the disease mediated by FXR, such as chronic intrahepatic or extrahepatic cholestasis, hepatic fibrosis caused by chronic cholestasis or acute intrahepatic cholestasis, chronic hepatitis B, gallstone, hepatic carcinoma, colon cancer or intestinal inflammatory disease, etc. Specifically, for some chemical compounds, their EC50 for FXR agonist activity reach below 100nM, which show an excellent FXR agonist activity and an excellent prospect to provide a new pharmaceutical selection in clinical treatment for the disease mediated by FXR.

SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE

The present invention provides new heteroaryl compounds, pharmaceutical acceptable salts and formulations thereof useful in preventing, treating or lessening the severity of JAK-mediated diseases. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of JAK-mediated diseases.

Benzopiperidine derivatives

Benzopiperidine derivatives represented by formula (I), salts thereof or hydrates thereof, processes for producing the same and drugs comprising the same: wherein the variables are as described in the specification. These compounds are useful as drugs efficacious in the prevention and treatment of these various inflammatory diseases and immunologic diseases, such as rheumatoid arthritis, atopic dermatitis, psoriasis, asthma, and rejection reaction accompanying organ transplantation.